Ann: Pre-Submission package lodged with the US FDA, page-32

So, respectfully,

The data that RAP have accrued via their "official" studies in hospitals etc are not to be trusted. The TGA and the CE teams thought differently and accepted the DATA. The FDA of course are a different animal...so perhaps it is now a step by step approach from RAP towards the FDA mindset. First a triage tool then a diagnostic tool with a few other steps in between to create the links that the FDA likes to see. I don't thnk this says that ResApp are going to be throwing everything at the new submission guidelines meetings...it seems to me to be a slower approach...after all this tech is going to either have a place in medical diagnostics/telehealth/ED triaging and third world applications or it isn't. The different organizations and companies now involved with RAP are not lightweight so it remains a weight...sorry wait and see with major upside as time passes. That is the issue for me and most others...a seemingly large lack of progress. How does one judge progress? Same as a resource stockthe company one way or another. It is just another wait in line and we will give you no real info announcement from RAP. ...the wait is long and lonely but in the end they either strike pay dirt and the numbers stack up or they don't.
Not much happiness in the RAP investor ranks ATM or for a fair while. Medgate to come...perhaps ResApp can bribe them to take up the tech that would hoodwink the market for awhile...like you are inferring ResApp is just one large hoodwink after another after another.
Sorry I don't buy that reasoning which you have seemingly gleaned from assuming various points of view after studying one aspect of their thrust. A request for a submission guidelines meeting with the FDA. Hardly substance and full of facts about the other processes and strategies that RAP are following.
Each to his own opinion of course! actually there is a lot more going on with RAP then just a submission guideline meeting request with the FDA...which nobody knows how it will turn out or affect any future marketing or use in the USA...it seems a good move as it positions ResApp as something not nothing in a massive marketplace. Once established there under whatever label the medical fraternity will get to use it and get to use it outside any box it has been pushed into. As long as they can get a toe hold then they can expand their influence.
We should all realize that ResApp is a slow burn with some mighty upside if a breakthrough in various areas occurs. Too much going for it to be classed as useless...unless as you seem to suggest the proven trials are just a hoodwink so far and the real results are far below what has been shown to date. That is drawing too long a bow and doesn't hold water. Wait for the impending adult trials forthcoming IMHO in the USA.
Don't forget the prestigious hospitals in the USA that have proven the tech beyond doubt several years ago...albeit in children. All on USA soil.
If anything I reckon they will end up doing adult trials in USA...so another year or two to wait...with luck Covid might be over by then and who knows what will be twixt now and then re new developments from RAP. I am not a happy shareholder but am willing to stay the course...Medgate dumping ResApdx will knock the stuffing out of RAP if they both can't swing a deal. That then is another tale so we wait and breathe...don't forget to breathe!